Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Intra-Cellular Therapies (Nasdaq: ITCI), a biopharmaceutical company specializing in central nervous system (CNS) disorders therapeutics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO and Chairman, Sharon Mates, Ph.D., will deliver a presentation on Monday, January 13, 2025, at 11:15 a.m. PT in San Francisco.
Interested parties can access both the live and archived versions of the presentation through the 'Events & Presentations' section of the company's website at www.intracellulartherapies.com. Attendees are advised to log in 5-10 minutes before the presentation to complete registration and software installation if necessary.
Intra-Cellular Therapies (Nasdaq: ITCI), una compagnia biofarmaceutica specializzata in terapie per disturbi del sistema nervoso centrale (SNC), ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. Il CEO e Presidente della società, Sharon Mates, Ph.D., terrà una presentazione lunedì 13 gennaio 2025, alle 11:15 ora del Pacifico a San Francisco.
Le parti interessate possono accedere sia alla versione in diretta che a quella registrata della presentazione attraverso la sezione 'Eventi e Presentazioni' del sito web della compagnia all'indirizzo www.intracellulartherapies.com. Si consiglia ai partecipanti di effettuare il login 5-10 minuti prima della presentazione per completare la registrazione e l'installazione del software, se necessario.
Intra-Cellular Therapies (Nasdaq: ITCI), una compañía biofarmacéutica especializada en terapias para trastornos del sistema nervioso central (SNC), ha anunciado su participación en la 43ª Conferencia Anual de Healthcare de J.P. Morgan. La CEO y presidenta de la compañía, Sharon Mates, Ph.D., dará una presentación el lunes 13 de enero de 2025, a las 11:15 a.m. PT en San Francisco.
Las partes interesadas pueden acceder tanto a la versión en vivo como a la archivada de la presentación a través de la sección 'Eventos y Presentaciones' en el sitio web de la compañía en www.intracellulartherapies.com. Se aconseja a los asistentes que inicien sesión de 5 a 10 minutos antes de la presentación para completar el registro y la instalación del software, si es necesario.
인트라 셀룰러 테라피(Intra-Cellular Therapies, Nasdaq: ITCI), 중추 신경계(CNS) 질환 치료에 전문화된 생명공학 회사가 제43회 J.P. 모건 헬스케어 콘퍼런스에 참가한다고 발표했습니다. 이 회사의 CEO이자 회장인 샤론 메이츠(Sharon Mates) 박사는 2025년 1월 13일 월요일, 오전 11:15 PT에 샌프란시스코에서 발표를 진행할 예정입니다.
관심 있는 사람들은 회사 웹사이트의 '이벤트 및 발표' 섹션을 통해 발표의 실시간 및 아카이브된 버전 모두에 접근할 수 있습니다. 참석자들은 발표 시작 5-10분 전에 로그인하여 등록 및 소프트웨어 설치를 완료할 것을 권장합니다.
Intra-Cellular Therapies (Nasdaq: ITCI), une société biopharmaceutique spécialisée dans les thérapeutiques pour les troubles du système nerveux central (SNC), a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. La PDG et Présidente de la société, Sharon Mates, Ph.D., présentera le lundi 13 janvier 2025, à 11h15 PT à San Francisco.
Les parties intéressées peuvent accéder à la fois à la version en direct et à la version archivée de la présentation via la section 'Événements et Présentations' du site internet de l'entreprise à www.intracellulartherapies.com. Il est conseillé aux participants de se connecter 5 à 10 minutes avant la présentation pour terminer l'inscription et l'installation du logiciel si nécessaire.
Intra-Cellular Therapies (Nasdaq: ITCI), ein biopharmazeutisches Unternehmen, das sich auf Therapien für Störungen des zentralen Nervensystems (ZNS) spezialisiert hat, gab seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz bekannt. Die CEO und Vorsitzende des Unternehmens, Sharon Mates, Ph.D., wird am Montag, den 13. Januar 2025, um 11:15 Uhr PT in San Francisco eine Präsentation halten.
Interessierte Parteien können sowohl die Live- als auch die archivierte Version der Präsentation über den Bereich 'Events & Präsentationen' auf der Unternehmenswebsite unter www.intracellulartherapies.com abrufen. Den Teilnehmern wird geraten, sich 5-10 Minuten vor Beginn der Präsentation anzumelden, um die Registrierung sowie die Softwareinstallation falls erforderlich abzuschließen.
- None.
- None.
BEDMINSTER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 11:15 a.m. PT in San Francisco, CA.
The live and archived webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.
Contact:
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333
Burns McClellan, Inc.
Cameron Radinovic
cradinovic@burnsmc.com
646-930-4406
FAQ
When is ITCI presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch ITCI's J.P. Morgan Healthcare Conference presentation?
What is the focus area of ITCI's therapeutic development?
Who will be presenting for ITCI at the 2025 J.P. Morgan Healthcare Conference?
